Merck & Co earnings were $17.4B for the trailing 12 months ending Mar 31, 2025, with 657.1% growth year over year. The latest MRK earnings report on Mar 31, 2025 announced Q1 2025 earnings of $5.1B, up 35.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, MRK reported annual earnings of $17.1B, with 4,589.6% growth.
MRK past earnings growth
How has MRK's earnings growth performed historically?
On MRK's earnings call on Invalid Date, Merck & Co (NYSE: MRK) reported Q1 2025 earnings per share (EPS) of $2.01, up 6.91% year over year. Total MRK earnings for the quarter were $5.08 billion. In the same quarter last year, Merck & Co's earnings per share (EPS) was $1.88.
As of the last Merck & Co earnings report, Merck & Co is currently profitable. Merck & Co's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $17.43 billion, a 656.03% increase year over year.
What was MRK's earnings growth in the past year?
As of Merck & Co's earnings date in Invalid Date, Merck & Co's earnings has grown 657.14% year over year. This is 542.97 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 114.17%. MRK earnings in the past year totalled $17.43 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.